Research - Clinical Research - Epilepsy
Faculty at the University of Toledo are currently involved in multiple areas of research in epilepsy. These Ìýinclude:
- Hormones and epilepsy
- Depression and epilepsy
- Bone density in patients on epilepsy medications
- Basic mechanisms of epilepsy
- New medications for treatment of epilepsy
Do you have uncontrolled partial seizures?Ìý
- We have ongoing studies involving oral tablets to add on to your current treatment (add-on therapy) or to take instead of your current treatment (monotherapy)
- ÌýIntended to test investigational drugs to see if they can reduce the frequency of seizures.
Current studies going on at the UTMC Neurology on epilepsy are:
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study To Evaluate The Efficacy And Safely Of Adjunctive Perampanel In Primary Generalized Tonic-Clonic Seizures. (E2007-G000-332)
- A Prospective, Multinational, Open-Label, Single Arm, Explorative Study To Evaluate The Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures (SP0980)
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study To Evaluate The Efficacy And Safety Of Brivaracetam In Subjects With Partial Onset Seizures. (NO1358)* (*Patients who complete N01358 study will be potentially eligible to enter an open-label, long term follow-up study with BRV)
- A Phase 2, Multicenter, Double-Blind, Randomized, Adjunctive Placebo-Controlled Trial to Evaluate the Efficacy and Safety of YKP3089 in Subjects with Treatment Resistant Partial Onset Seizures; Protocol # YKP3089C013; Sponsor: SK Life Sciences
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Clinical Trail; BIA2093-304; Sponsor: Sunovian
- LONG TERM ESLICARBAZEPINE ACETATE MONOTHERAPY EXTENSION STUDY; Protocol # 093- 050; SPONSOR:Ìý Sunovion, Inc. (*This is the second, extension phase of the double blind eslicarbazepine acetate monotherapy study 093-045 that we completed)Ìý
- A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures; Protocol# SP904; Sponsor:Ìý UCB
For more Information please contact:
Kim Cole,ÌýDNP * 419-383-6783 * kimberly.cole@utoledo.edu
Ìý
Ìý